Investment Counselors of Maryland LLC boosted its holdings in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 1.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 279,979 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,100 shares during the period. Investment Counselors of Maryland LLC owned approximately 2.32% of ANI Pharmaceuticals worth $23,014,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of ANIP. Dimensional Fund Advisors LP grew its holdings in ANI Pharmaceuticals by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 518,427 shares of the specialty pharmaceutical company’s stock worth $23,339,000 after purchasing an additional 6,546 shares during the period. Phocas Financial Corp. grew its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Phocas Financial Corp. now owns 140,977 shares of the specialty pharmaceutical company’s stock worth $9,945,000 after purchasing an additional 11,501 shares during the period. Geode Capital Management LLC grew its holdings in ANI Pharmaceuticals by 3.0% in the fourth quarter. Geode Capital Management LLC now owns 97,459 shares of the specialty pharmaceutical company’s stock worth $4,387,000 after purchasing an additional 2,827 shares during the period. Global Alpha Capital Management Ltd. purchased a new stake in ANI Pharmaceuticals in the first quarter worth about $6,808,000. Finally, LSV Asset Management grew its holdings in ANI Pharmaceuticals by 28.0% in the first quarter. LSV Asset Management now owns 81,785 shares of the specialty pharmaceutical company’s stock worth $5,769,000 after purchasing an additional 17,885 shares during the period. 67.00% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on ANIP shares. Cantor Fitzgerald restated a “buy” rating and issued a $89.00 price objective on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. BidaskClub cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Raymond James cut shares of ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and upped their price objective for the stock from $73.00 to $82.00 in a report on Friday, May 10th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $89.00.

In other news, major shareholder Meridian Venture Partners Ii L sold 61,697 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $71.64, for a total transaction of $4,419,973.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David Nash purchased 1,445 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were purchased at an average price of $68.76 per share, for a total transaction of $99,358.20. Following the acquisition, the director now owns 5,236 shares of the company’s stock, valued at $360,027.36. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 90,872 shares of company stock worth $6,489,837. Corporate insiders own 24.70% of the company’s stock.

Shares of NASDAQ:ANIP traded down $0.22 during trading on Wednesday, reaching $67.14. 7,434 shares of the stock traded hands, compared to its average volume of 164,390. The stock has a 50-day moving average of $79.08 and a two-hundred day moving average of $70.62. ANI Pharmaceuticals Inc has a 52-week low of $36.92 and a 52-week high of $86.96. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 1.01. The stock has a market cap of $831.81 million, a P/E ratio of 14.55 and a beta of 2.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.18 by $0.26. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The firm had revenue of $54.36 million for the quarter, compared to analysts’ expectations of $55.20 million. During the same quarter in the prior year, the company posted $1.13 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. Sell-side analysts expect that ANI Pharmaceuticals Inc will post 5.29 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Recommended Story: Technical Analysis of Stocks and What It Means

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.